Tag:

cold

Health

New Breast Cancer Classification Predicts Immunotherapy Success

by Chief Editor
written by Chief Editor

Researchers from the Department of Breast Surgery at Fudan University Shanghai Cancer Center and the Department of Oncology at Shanghai Medical College, Fudan University have developed a new classification system for breast cancer based on the cancer-immunity cycle (CIC). Published in Cancer Biology & Medicine in 2026, this framework uses a “CIC score” to categorize patients into three distinct clusters, identifying specific immune-evasion mechanisms that predict how tumors respond to immune checkpoint inhibitors (ICIs).

How the CIC Score Classifies Breast Cancer

The anti-tumor immune response follows a specific sequence, starting with the release of cancer antigens and ending with the destruction of malignant cells. According to the study published in Cancer Biology & Medicine (DOI: 10.20892/j.issn.2095-3941.2025.0611), a breakdown at any stage in this cycle can cause immunotherapy to fail.

How the CIC Score Classifies Breast Cancer

The research team created a scoring system to measure the efficiency of six key steps in this cycle. Based on these scores, patients are grouped into three clusters:

  • C1 (Immune-Cold): Characterized by low immune infiltration and a high presence of immunosuppressive M2 macrophages. These patients typically face a poor prognosis.
  • C2 (Intermediate): A unique subtype defined by a defect in antigen presentation. Despite having a high tumor mutational burden, these patients struggle to respond to standard ICIs.
  • C3 (Immune-Hot): These tumors show high levels of active T cells and immune cell infiltration, making them the most responsive group for ICI therapy.
Pro Tip: Unlike traditional “hot” and “cold” tumor models, the CIC scoring system highlights exactly where the immune response is breaking down, allowing for more precise treatment selection.

Why the C2 Subtype Challenges Current Immunotherapy

The C2 subtype presents a complex hurdle for clinicians. According to the researchers, these tumors possess a high tumor mutational burden, which generally signals that a patient might respond well to immunotherapy. However, C2 tumors exhibit frequent human leukocyte antigen (HLA) loss of heterozygosity.

This genetic loss prevents the immune system from effectively “seeing” the cancer. Furthermore, the tumor microenvironment in C2 patients is crowded with dysfunctional dendritic cells and regulatory T cells (Tregs). Multi-omic analyses revealed that C2 tumors are heavily dependent on serine metabolism, specifically identifying the enzyme PSAT1 as a key regulator. Knocking down PSAT1 in cancer cells reduced the expression of immunosuppressive molecules like PD-L1 and TGFB1.

Future Trends in Targeted Combination Therapy

The development of the CIC score suggests a shift toward personalized, mechanism-based combination therapies. Rather than applying a one-size-fits-all approach to immunotherapy, future clinical strategies may be tailored to the specific “break” in the cycle identified by the score.

[Visual History Project] Liu Luming – Integrative Oncology at Fudan University Cancer Hospital

For C1 patients, the goal is to convert an “immune-cold” environment into a “hot” one. For C2 patients, researchers point toward strategies that enhance antigen presentation, such as targeting the PSAT1 enzyme or overcoming HLA loss. This data-driven approach aims to expand the range of patients who benefit from ICIs while sparing those unlikely to respond from unnecessary treatment side effects.

Frequently Asked Questions

What is the cancer-immunity cycle?

It is a conceptual framework mapping the steps the immune system takes to identify and destroy tumor cells, from antigen release to the final killing of the cell.

Why do some breast cancer patients not respond to ICIs?

According to the study, patients often fail to respond because of a “break” or defect in one of the six steps of the cancer-immunity cycle.

What is the significance of the PSAT1 enzyme?

PSAT1 was identified as a metabolic regulator in the C2 subtype. Researchers found that targeting this enzyme can reduce immunosuppressive markers, potentially making tumors more vulnerable to treatment.

Want to keep up with the latest in cancer research?

Subscribe to our newsletter for updates on oncology breakthroughs and clinical trial news.

0 comments
0 FacebookTwitterPinterestEmail
Health

New Experimental Drug Protects Nerve Cells From ALS Damage

by Chief Editor
written by Chief Editor

University of Arizona researchers have developed an experimental drug, XL20, that shows potential to protect nerve cells from damage associated with amyotrophic lateral sclerosis (ALS). According to a study published in Nature Aging, the drug targets a specific region of the TDP-43 protein to prevent toxic clumping, a process that contributes to neurodegeneration in ALS and other age-related conditions.

How does the experimental drug XL20 work?

The drug XL20 functions by latching onto a specific, conserved region of the TDP-43 protein. Research led by Xinglong Wang, a professor at the R. Ken Coit College of Pharmacy, identified this region as a primary driver of protein toxicity. By targeting this area, the drug prevents the protein from forming harmful clumps inside nerve cells without interfering with its normal, healthy functions. According to the study, XL20 is capable of crossing the blood-brain barrier, a critical requirement for treating neurological conditions.

Did you know?
The protein TDP-43 is essential for normal cell function. In ALS patients, it drifts out of its proper location in the brain’s nerve cells, forming toxic clumps that are now used to confirm an ALS diagnosis during autopsies.

Why has ALS been historically difficult to treat?

ALS is challenging to address because symptoms often appear only after significant nerve cell damage has already occurred. According to Wang, the first signs—such as limb weakness—frequently mask the fact that the disease has been progressing. While nearly all ALS cases involve TDP-43 pathology, fewer than one in 10 cases are inherited. The remaining cases arise sporadically, making it difficult to predict or treat the disease before the onset of severe motor neuron loss.

How does this research impact other neurodegenerative diseases?

The implications of the XL20 study extend beyond ALS. The same TDP-43 abnormality is a hallmark of limbic-predominant age-related TDP-43 encephalopathy (LATE), a dementia affecting roughly one in three people over the age of 80. Furthermore, TDP-43 pathology is present in more than half of all Alzheimer’s disease patients, where it is linked to accelerated cognitive decline. Wang suggests that if this targeted approach proves effective in future clinical development, it could offer a therapeutic avenue for a much broader range of neurodegenerative conditions.

Comparison: Current Treatments vs. Experimental Approaches

Treatment Type Key Characteristic
Current FDA-approved drugs Provide only modest benefits for patients.
XL20 (Experimental) Directly targets TDP-43 clumping to protect nerve cells.

Frequently Asked Questions

What is the status of XL20?

XL20 has shown success in mouse models, where it extended median survival and reduced muscle weakness. It has also been tested on human motor neurons in lab settings, where it reversed some of the same damage. It is currently a candidate for future clinical development.

Mayo Clinic ALS Study

Is the damage caused by TDP-43 reversible?

In laboratory testing on human motor neurons, the experimental drug XL20 successfully reversed some of the damage caused by TDP-43, according to the research team.

Does this drug affect healthy protein function?

No. According to Ju Gao and Xinglong Wang, the research team spent a decade confirming that deleting the target region—and using the drug to block it—does not disturb the protein’s normal, necessary functions within the cell.

Pro Tip:
Early intervention remains the gold standard for neurodegenerative diseases. As research into drugs like XL20 continues, stay informed on clinical trial registries to track the progress of potential breakthroughs for ALS and related dementias.

Are you interested in the latest developments in neurodegenerative research? Subscribe to our newsletter for updates on breakthroughs in ALS and dementia treatments.

0 comments
0 FacebookTwitterPinterestEmail
Health

Reviving Vancomycin: Groundbreaking Strategy Shows Promise Against Resistant Bacteria

by Chief Editor
written by Chief Editor

Breakthrough in Antibiotic Resistance: Targeting Bacterial Enzymes

How the Study Uncovered a New Approach

Antibiotic resistance, a global health crisis linked to 4.7 million deaths in 2019, has seen a critical breakthrough. Researchers at Scripps Research discovered that disabling a bacterial enzyme called secreted antigen A (SagA) makes vancomycin-resistant Enterococcus faecium (VREfm) vulnerable to vancomycin. The study, published in *Nature Communications* on June 16, 2026, revealed that genetic deletion of SagA reduced the bacteria’s ability to divide, increasing susceptibility to the antibiotic.

According to Howard Hang, a professor at Scripps Research, “SagA remodels the cell wall so bacteria divide properly. Disrupting it makes the bacteria more sensitive to vancomycin.” The team also identified a chemical compound, pghi-4, which chemically blocks SagA, cutting the required vancomycin dose by up to 8-fold in lab tests.

Real-World Implications for Hospital Infections

VREfm, a hospital-acquired infection, is resistant to multiple antibiotics, including vancomycin. The study’s success in a mouse model of sepsis suggests the approach could translate to human treatments. “This is a promising new weapon in the arms race against antibiotic resistance,” Hang said.

The research highlights the potential of antibiotic adjuvants—compounds that enhance existing drugs. Unlike previous adjuvants, this strategy targets a family of enzymes (NlpC/P60 peptidoglycan hydrolases) never before successfully inhibited.

Future Potential and Challenges

Future Potential and Challenges

The study’s findings open avenues for combating other resistant pathogens, such as tuberculosis and drug-resistant *Staphylococcus aureus*. Researchers are already developing second-generation compounds that combine pghi-4 with vancomycin.

However, challenges remain. VREfm strains often carry multiple SagA-like enzymes, which could reduce the treatment’s effectiveness. Scientists are investigating whether targeting these additional enzymes could broaden the approach.

Why This Matters for Global Health

Antibiotic Resistance: A Growing Threat

Antibiotic resistance is now classified as a “global health emergency” by the World Health Organization. In 2019, it contributed to 4.7 million deaths worldwide, with infections like VREfm becoming increasingly difficult to treat.

The Scripps study addresses a key gap: how to restore the efficacy of last-resort antibiotics. By targeting bacterial physiology rather than directly killing pathogens, the approach could delay the emergence of new resistances.

Comparing Past and Present Strategies

Comparing Past and Present Strategies

Traditional methods to combat resistance focus on developing new antibiotics, a process that takes years and costs billions. In contrast, adjuvants like pghi-4 offer a faster, more cost-effective solution. For example, while new antibiotics for VREfm have been scarce, this study demonstrates how existing drugs can be revitalized.

What’s Next for Antibiotic Research?

Expanding the Scope of Adjuvant Therapies

The success of pghi-4 has sparked interest in targeting other NlpC/P60 enzymes. Researchers are testing whether similar compounds could work against other resistant bacteria, including *E. coli* and *Pseudomonas aeruginosa*.

Hang emphasized the broader lesson: “Targeting basic bacterial processes can overcome resistance.” This aligns with recent studies showing that disrupting cell-wall synthesis or metabolic pathways can enhance antibiotic effectiveness.

Regulatory and Clinical Hurdles

Before clinical trials, the team must ensure the compounds are safe for human use. Animal studies showed reduced bacterial burden, but human trials are needed to confirm efficacy. Regulatory agencies like the FDA will likely require extensive testing before approval.

FAQ: Answers to Common Questions

What is vancomycin-resistant Enterococcus faecium (VREfm)?

VREfm is a type of bacteria that causes hospital-acquired infections and is resistant to multiple antibiotics, including vancomycin, a last-resort treatment.

Why is targeting SagA a breakthrough?

SagA is a key enzyme in bacterial cell-wall remodeling. Disabling it makes VREfm vulnerable to vancomycin, offering a way to revive an existing antibiotic without developing new ones.

Are there risks of side effects with this approach?

The study found no significant toxicity in mouse models, but human trials are needed to confirm safety. Researchers are also exploring whether the compound affects beneficial bacteria.

Did You Know?

Vancomycin, once considered a “last resort,” is now less effective against VREfm. The new approach could extend its usefulness for years.

FAQ: Answers to Common Questions

Pro Tips for Staying Informed

Follow updates from the Scripps Research Institute and *Nature Communications* for developments in antibiotic adjuvants. Public health organizations like the WHO also track resistance trends globally.

Explore More

Learn how other innovations, like CRISPR-based therapies, are tackling antibiotic resistance. Visit our special report for deeper insights.

Call to Action

Stay ahead of the curve in medical advancements. Subscribe to our newsletter for regular updates on breakthroughs in global health. Share this article to spread awareness about the fight against antibiotic resistance.

0 comments
0 FacebookTwitterPinterestEmail
Health

Identifying the methodology gap that prevents treatment of infection-triggered chronic diseases

by Chief Editor
written by Chief Editor

Beyond the ‘Brain Fog’: Why the Future of Chronic Illness Treatment Depends on Better Science

For millions of people living with the aftermath of an infection, the medical experience is often a frustrating cycle of “invisible” symptoms and inconclusive tests. Whether This proves the lingering exhaustion of Long COVID, the cognitive haze of post-treatment Lyme disease syndrome, or the debilitating fatigue of ME/CFS, the common thread is a lack of definitive answers.

From Instagram — related to Brain Fog, Better Science

However, a shift is occurring in the scientific community. Leading researchers from institutions like the National Institutes of Health (NIH) and Rutgers University are pointing to a critical “methodology gap.” The problem isn’t necessarily a lack of effort, but a lack of rigor in how studies are designed.

Did you know? Antibody tests—often used to diagnose Lyme disease—only show that your body encountered a pathogen in the past. They do not prove that an active infection is currently driving your symptoms.

The End of ‘Lumping’: The Rise of Patient Stratification

One of the most significant trends in upcoming medical research is the move away from “lumping.” For years, patients with Long COVID or chronic fatigue have been grouped into a single category. In reality, these populations are likely composed of several different biological subgroups.

Future trends suggest a move toward patient stratification. Instead of treating “Long COVID” as one disease, researchers will likely divide patients based on specific biomarkers or clinical phenotypes. For example, one group may suffer from vascular inflammation, while another deals with autoimmune dysfunction.

By isolating these distinct groups, clinical trials can move from a “shotgun approach” to precision medicine. When the right treatment meets the right biological profile, the success rate of FDA-approved therapies will skyrocket.

The ‘MS Blueprint’ for Success

We have seen this work before. Multiple Sclerosis (MS) was once a poorly understood condition with vague diagnostic criteria. By implementing rigorous study designs and identifying specific biological markers, the medical community developed a suite of highly effective, FDA-approved treatments.

The 'MS Blueprint' for Success
Success

The goal now is to apply that same rigor to infection-triggered illnesses. This means moving past “self-reported” histories and requiring objective proof of the causative pathogen before a patient enters a clinical trial.

Pro Tip: If you are managing chronic post-infectious symptoms, keep a detailed “symptom map.” Documenting the exact timing of your infection, the specific medications used, and the progression of symptoms can help your specialist categorize your case more accurately.

Next-Gen Diagnostics: Hunting the Pathogen

The future of treating conditions like post-treatment Lyme disease syndrome relies on our ability to see what was previously invisible. The bacterium Borrelia burgdorferi is notoriously challenging to detect once it leaves the bloodstream and enters the tissues.

Next-Gen Diagnostics: Hunting the Pathogen
Instead

We are moving toward a new era of metagenomic sequencing and high-sensitivity PCR tests. Instead of relying on the body’s immune response (antibodies), these tools look for the genetic signature of the pathogen itself.

As these tools become standard in clinical settings, the “diagnostic gap” will close. We will no longer have to guess if a patient has a mimicking condition—such as a drug reaction or a different tick-borne illness—because the evidence will be written in the DNA.

AI and the Search for Biomarkers

Artificial Intelligence is set to play a pivotal role in solving the mystery of “brain fog” and chronic fatigue. Because these symptoms are subjective, they are hard to measure in a lab. AI can change that by analyzing massive datasets of patient proteomics and metabolomics.

By comparing thousands of “sick” profiles against “healthy” control groups, AI can identify subtle chemical signatures in the blood or cerebrospinal fluid that human researchers might miss. This will turn a subjective feeling of “fatigue” into a measurable biological data point.

For more on how technology is reshaping healthcare, check out our guide on the evolution of digital diagnostics.

Frequently Asked Questions

Why are current Lyme disease tests often considered insufficient?
Many tests detect antibodies rather than the bacteria itself. Since antibodies can persist long after an infection is gone, or be triggered by similar pathogens, they cannot confirm an active, ongoing infection.

What is ‘brain fog’ from a medical perspective?
While not a formal diagnosis, “brain fog” usually refers to cognitive impairment involving deficits in executive function, memory, and attention, often triggered by systemic inflammation or neurological dysfunction following an infection.

Can Long COVID be treated if the virus is gone?
Yes. The trend in research suggests that while the initial virus may be cleared, the infection may have triggered an autoimmune response or left behind “viral reservoirs” that continue to cause inflammation.

Join the Conversation

Are you or a loved one navigating the complexities of a post-infectious illness? Do you believe better diagnostic rigor is the key to a cure?

Share your experience in the comments below or subscribe to our newsletter for the latest updates in medical breakthroughs.

Subscribe for Updates

0 comments
0 FacebookTwitterPinterestEmail
Sport

Will Jordan’s Morning Routine

by Chief Editor
written by Chief Editor

The Morning Routines of High Achievers: A Deep Dive into Will Jordan’s Day Starter

Will Jordan’s Morning Routine: A Glimpse into the Life of an All Blacks Star

Will Jordan, the renowned All Blacks and Crusaders star, recently shared his morning routine with the New Zealand Herald. Let’s dive into the habits and rituals that help this elite athlete kickstart his day.

Starting the Day: 6:15 AM

Will Jordan’s day begins at 6:15 AM, when he wakes up to tend to his energetic 2-year-old cocker spaniel, Lenny. This furry companion helps Jordan get going and sets the tone for an active day ahead.

From Instagram — related to Starting the Day, Cold Showers

Cold Showers: A Refreshing Wake-Up Call

In a unique twist, Jordan and his Crusaders teammate, Mitch Drummond, have started each day with a cold shower. Jordan admits that it’s not always effortless, but it’s an invigorating way to reset and feel fresh.

Coffee and Breakfast: Fueling the Body

After his cold shower, Jordan makes himself a coffee – a non-negotiable morning ritual. He follows this up with breakfast, typically around 6:30 AM, consisting of pre-prepared overnight oats with a variety of nuts, seeds, and berries.

Training and Workouts: An Athlete’s Daily Grind

As an athlete, Jordan spends a significant part of his morning on training and skill work. He arrives at training around 7:15 AM, starting with a stretch and individual skill work, followed by a personalized workout tailored to his position on the field.

Mindfulness and Self-Care: More Than Just Physical Fitness

Jordan’s morning routine also includes mindfulness and self-care practices. He takes a mindful walk to work, setting intentions for the day, and practices breath control during his cold showers. He keeps his skincare routine simple yet effective, using products from La Roche-Posay.

Style and Technology: Balancing Expression and Minimalism

Jordan keeps his morning phone use to a minimum, spending around 10 minutes catching up on news and notifications. He prefers to keep his mind clear and present during his walk to work. When it comes to his outfit, he keeps it practical and expressive, with team kits for training and expressive golf outfits on his days off.

Style and Technology: Balancing Expression and Minimalism
Routines

The Power of Morning Routines: Insights from High Achievers

Will Jordan is not alone in his commitment to a structured morning routine. Many successful individuals, from entrepreneurs to celebrities, swear by the transformative power of starting the day on the right foot.

Did you know? According to a survey by the U.S. Bureau of Labor Statistics, people who wake up early tend to exercise more, work more, and even have more sex than late risers (Source: The Atlantic).

The Art of Crafting Your Own Morning Routine

Creating a morning routine that works for you is a personal journey. Here are some tips to help you get started:

The Art of Crafting Your Own Morning Routine
Up Call
  1. Find Your Wake-Up Call: Whether it’s a furry companion, a meditation practice, or a cold shower, find what gets you out of bed and ready to face the day.
  2. Mindfulness and Intention Setting: Incorporate mindfulness into your morning routine to help you stay present and focused throughout the day.
  3. Fuel Your Body: Eat a healthy breakfast to give you the energy you need to tackle your day.
  4. Make Time for Exercise: Even a short walk or some stretching can make a significant difference in your mood and productivity.
  5. Keep Technology in Check: While it’s tempting to reach for your phone first thing in the morning, try to limit your screen time and engage with technology mindfully.

FAQs: Your Morning Routine Questions Answered

Q: How much sleep does Will Jordan get each night? A: Jordan typically gets between 5 to 7 hours of sleep per night, going to bed between 11:00 PM and 1:00 AM.

Q: Does Will Jordan make his bed every day? A: Jordan admitted that he doesn’t always make his bed, but he tries to tidy it when he’s up before his fiancée, Mackenzie Webb.

Q: What does Will Jordan do to prepare for the next day? A: Jordan plans his week ahead by writing down a week plan, including meetings, work-ons, and any key tasks. He also packs his bag and sets out his outfit for the next day to streamline his morning routine.

Ready to Transform Your Mornings? Start Here!

Crafting the perfect morning routine takes time and experimentation. Don’t be afraid to try new habits and adjust them as needed. The key is to find what works best for you and stick to it.

So, what are you waiting for? Start your day right and unlock the power of a well-crafted morning routine. Your future self will thank you!

Have you tried any of Will Jordan’s morning routine habits? Share your experiences and tips in the comments below!

Sources: [1] All Blacks and Crusaders star Will Jordan shares his morning routine [2] The Power of Morning Routines

0 comments
0 FacebookTwitterPinterestEmail
Tech

The molecular mechanism that turns cool temps into nerve signals

by Chief Editor
written by Chief Editor

Unlocking the Secrets of Cold: How New Discoveries Could Revolutionize Pain Treatment

The sensation of cold, from the bracing chill of an ice cube to the soothing coolness of menthol, has long been a scientific puzzle. Now, researchers at UC San Francisco have made a breakthrough in understanding how our bodies detect temperature, specifically focusing on a protein called TRPM8. This discovery, published in Nature on March 25th, 2026, not only explains a fundamental aspect of human physiology but also opens doors for novel pain therapies.

The TRPM8 Channel: A Gatekeeper of Cold Sensation

TRPM8, found in nerve cells, acts like a tiny gate, opening to signal the brain when temperatures drop. For years, scientists have known TRPM8’s role in sensing cold and the cooling effect of menthol, but its precise mechanism remained elusive. The challenge lay in visualizing the protein’s dynamic changes as it responded to temperature fluctuations. Traditional structural biology often focuses on capturing proteins in stable states, missing crucial information about their movement.

“Everyone always wants to understand how temperature sensing works, but it turns out to be a very technically challenging question to answer. So, to finally have insight into This represents really very exciting,” stated a researcher involved in the study.

A New Approach to Protein Imaging

The UCSF team overcame this hurdle by imaging TRPM8 while it remained embedded in cell membranes. This approach proved critical, as isolating the protein caused it to fall apart. They employed two powerful techniques: cryo-electron microscopy (cryo-EM) for static snapshots and hydrogen-deuterium exchange mass spectrometry (HDX-MS) to track the protein’s movements in real-time.

“Just as looking at a photo of a horse can’t tell you how prompt it runs, the electron microscopy alone can’t tell us how the molecule moves and what drives those movements,” explained a co-first author of the study. “But combining these two techniques gave us a window into what was happening.”

How Cold Activates TRPM8: A Molecular Dance

The analysis revealed that cold stabilizes a specific region of the TRPM8 channel, triggering a helix to move. This movement allows a lipid molecule to slide into place, locking the channel open and sustaining the cold signal. Comparing human TRPM8 to its avian counterpart – which is less sensitive to cold but responds to menthol – helped pinpoint the features responsible for cold detection.

Implications for Pain Management and Beyond

This research has significant implications for treating conditions like cold allodynia, where even mild cold triggers severe pain. Several compounds that block TRPM8 are currently in clinical trials and understanding the protein’s structure could lead to more targeted and effective therapies. Researchers are now applying this same strategy to study TRPV1, the heat-sensing channel discovered by Nobel laureate Julius in 1997.

The Future of Structural Biology: Capturing Movement

The success of this study highlights a shift in structural biology, emphasizing the importance of understanding protein dynamics. “The lessons we learned in studying this channel are actually very broadly useful,” noted a researcher. “Dynamic behavior is critical for the function of many proteins, and you can’t understand dynamic behavior from one snapshot of a protein’s structure.”

Did you know? The researcher who led this study also won the 2021 Nobel Prize in Physiology or Medicine for his earlier work on the heat-sensing protein TRPV1.

Frequently Asked Questions

Q: What is TRPM8?
A: TRPM8 is a protein in nerve cells that acts as a sensor for cold temperatures and the cooling sensation of menthol.

Q: Why was it difficult to study TRPM8?
A: TRPM8 is unstable when isolated from cells and traditional imaging methods require stable protein structures.

Q: How did researchers overcome these challenges?
A: They imaged TRPM8 while it was still embedded in cell membranes, using cryo-EM and HDX-MS.

Q: What are the potential applications of this research?
A: It could lead to new treatments for pain conditions like cold allodynia.

Pro Tip: Maintaining optimal body temperature is crucial for overall health. Dress appropriately for the weather and stay hydrated to support your body’s natural temperature regulation mechanisms.

Aim for to learn more about the fascinating world of sensory biology? Explore our other articles on neuroscience and pain management.

0 comments
0 FacebookTwitterPinterestEmail
Health

New pathway enhances brown fat thermogenesis and metabolic health

by Chief Editor
written by Chief Editor

The Future of Obesity Treatment: Wiring Up Brown Fat for Calorie Burning

For decades, the fight against obesity has centered on reducing calorie intake. But what if we could simply increase calorie expenditure? Emerging research suggests a powerful, and often overlooked, ally in this battle: brown fat. Recent breakthroughs, published in Nature Communications, are revealing the intricate mechanisms that control brown fat’s calorie-burning potential, opening doors to innovative therapies that could reshape how we approach weight management.

Understanding Brown Fat: More Than Just Heat

Most body fat is white adipose tissue (WAT), which stores energy. Brown adipose tissue (BAT), however, is a specialized fat that generates heat – a process called thermogenesis. This happens when BAT rapidly uses glucose and lipids, effectively acting as a “metabolic sink” that prevents energy from being stored as white fat. While humans have less brown fat than animals, its presence is strongly linked to metabolic health and weight loss.

The SLIT3 Discovery: A Key to Unlocking Brown Fat’s Potential

Researchers at NYU College of Dentistry have identified a crucial protein, SLIT3, secreted by brown fat cells. This protein isn’t a simple on/off switch; it’s cleverly designed. SLIT3 is cleaved into two fragments by an enzyme called BMP1, and each fragment plays a distinct role. One fragment stimulates the growth of blood vessels within the fat tissue, while the other expands the network of nerves. This coordinated development of both vascular and nervous systems is essential for brown fat to function optimally.

“It works as a split signal, which is an elegant evolutionary design in which two components of a single factor independently regulate distinct processes that must be tightly coordinated in space and time,” explains Farnaz Shamsi, the study’s senior author.

The Neurovascular Connection: Why Infrastructure Matters

Previous research focused on stimulating brown fat cells to generate heat. This new work highlights the importance of the infrastructure supporting those cells. Nerves enable communication between brown fat and the brain, triggering activation in response to cold. Blood vessels deliver oxygen and nutrients, fueling the heat-generating process. Without a robust network of both, brown fat’s calorie-burning capacity is severely limited.

Studies in mice demonstrated the critical role of SLIT3. Removing the protein or its receptor, PLXNA1, resulted in cold sensitivity and impaired thermogenesis, alongside a lack of proper nerve structure and blood vessel density in the brown fat.

Human Relevance: Gene Expression and Obesity

The findings aren’t limited to animal models. Researchers analyzed fat tissue samples from over 1,500 people, including individuals with obesity. They found that gene expression related to SLIT3 may regulate fat tissue health, inflammation, and insulin sensitivity in people with obesity. This suggests the SLIT3 pathway could be a relevant target for treating metabolic disorders in humans.

Beyond Appetite Suppression: A New Era of Obesity Treatments?

Current weight loss drugs, like GLP-1s, primarily work by suppressing appetite. While effective, this approach focuses on reducing energy intake. Therapies targeting brown fat, however, offer the potential to increase energy expenditure. By harnessing the mechanisms controlling SLIT3 and its downstream effects on blood vessels and nerves, scientists may be able to “wire up” brown fat for maximum calorie burning.

Future Trends and Potential Therapies

The discovery of SLIT3’s role opens several avenues for future research and therapeutic development:

  • SLIT3 Agonists: Developing drugs that mimic the effects of SLIT3 fragments could stimulate the growth of blood vessels and nerves in brown fat, enhancing its activity.
  • BMP1 Modulation: Targeting the BMP1 enzyme could control the cleavage of SLIT3, fine-tuning the balance between vascular and nervous system development.
  • PLXNA1 Activation: Finding ways to activate the PLXNA1 receptor could directly stimulate the nerve network within brown fat.
  • Personalized Medicine: Analyzing an individual’s SLIT3 gene expression could help identify those most likely to benefit from brown fat-activating therapies.

FAQ

Q: What is brown fat?
A: Brown fat is a specialized type of fat tissue that generates heat by burning calories, unlike white fat which stores energy.

Q: How does SLIT3 work?
A: SLIT3 is a protein secreted by brown fat that, when split into two fragments, controls the growth of blood vessels and nerves essential for its function.

Q: Could this research lead to a cure for obesity?
A: While it’s too early to say, this research offers a promising new approach to obesity treatment by focusing on increasing energy expenditure rather than just reducing intake.

Q: Is brown fat activation safe?
A: More research is needed to determine the long-term safety of brown fat-activating therapies.

Did you know? Mice typically have more active brown fat than humans, allowing them to tolerate cold temperatures for longer periods.

Pro Tip: While research is ongoing, maintaining a healthy lifestyle with regular exercise and a balanced diet can support overall metabolic health and potentially enhance brown fat activity.

Want to learn more about the latest breakthroughs in metabolic health? Explore our other articles or subscribe to our newsletter for updates.

0 comments
0 FacebookTwitterPinterestEmail
Health

Covid long: Bacteria in nose could predict & prevent long-term symptoms

by Chief Editor
written by Chief Editor

The Emerging Link Between Gut Bacteria and Long COVID Recovery

For many, the battle against COVID-19 doesn’t end with a negative test. Long COVID, characterized by persistent symptoms like fatigue, brain fog, and respiratory issues, continues to affect millions. While the exact causes remain elusive, a growing body of research points to a surprising player: the microbiome, specifically the bacteria residing in our respiratory system.

A Bacterial Imbalance and Persistent Inflammation

Recent studies, including research from the UCLouvain and Cliniques universitaires Saint-Luc in Belgium, have identified a potential link between the abundance of certain gut bacteria and the development of Long COVID. Researchers discovered that individuals who went on to develop Long COVID had lower levels of Dolosigranulum pigrum, a bacterium naturally found in the respiratory microbiome, during the acute phase of infection. This suggests that a disruption in the delicate balance of these microbial communities could play a role in the persistence of symptoms.

This finding aligns with broader research indicating that Long COVID is often characterized by persistent inflammation. Inflammation after SARS-CoV-2 infections has been shown to cause damage to organs like the lungs and kidneys, and even affect brain function, as demonstrated in studies on hamsters. The Harvard Gazette reported that those with the greatest inflammation at the start of infection were more likely to experience lingering symptoms, suggesting the initial immune response can, in some cases, set the stage for Long COVID.

The Role of the Microbiome in Immune Response

The connection between gut bacteria and immune function is well-established. The microbiome influences the development and regulation of the immune system, and imbalances can contribute to chronic inflammation. Researchers hypothesize that Dolosigranulum pigrum may play a protective role by modulating the immune response and preventing excessive inflammation. A disrupted microbiome could therefore leave individuals more vulnerable to the long-term effects of COVID-19.

This isn’t an isolated observation. Studies have shown that Long COVID involves activation of proinflammatory and immune responses, with upregulation of pathways related to inflammation and immune dysfunction. The Nature article highlights that these persistent immune activations are observed even 18 months after initial infection.

Potential Therapeutic Strategies: Restoring Microbial Balance

The identification of Dolosigranulum pigrum as a potential protective bacterium opens up exciting possibilities for therapeutic intervention. One promising avenue is the development of targeted therapies aimed at restoring microbial balance in the respiratory system. This could involve:

  • Probiotic Sprays: Nasal sprays containing Dolosigranulum pigrum or other beneficial bacteria could facilitate colonize the respiratory tract and bolster the immune response.
  • Prebiotic Interventions: Dietary or supplemental prebiotics could nourish existing beneficial bacteria and promote their growth.
  • Fecal Microbiota Transplantation (FMT): While more invasive, FMT – transferring fecal matter from a healthy donor to a recipient – is being explored as a potential treatment for various microbiome-related conditions.

However, researchers caution that these approaches are still in the early stages of development. Further research is needed to understand the precise mechanisms by which Dolosigranulum pigrum exerts its protective effects and to ensure the safety and efficacy of any interventions.

The Importance of Responsible Antibiotic Use

The study similarly underscores the importance of responsible antibiotic use. Antibiotics, while essential for treating bacterial infections, can disrupt the microbiome, potentially eliminating beneficial bacteria like Dolosigranulum pigrum. This disruption could increase susceptibility to Long COVID or exacerbate existing symptoms.

Pro Tip: Avoid unnecessary antibiotic use. Consult with your doctor to determine if antibiotics are truly needed for your condition.

Future Research Directions

The research community is actively pursuing several key areas of investigation:

  • Understanding the Mechanisms: Researchers are working to unravel the precise mechanisms by which Dolosigranulum pigrum protects against Long COVID.
  • Identifying Other Key Bacteria: Identifying other bacterial species that may contribute to or protect against Long COVID.
  • Developing Targeted Therapies: Developing and testing targeted therapies aimed at restoring microbial balance.
  • Personalized Medicine: Tailoring treatment strategies based on an individual’s microbiome profile.

FAQ

Q: Can I improve my gut health to prevent Long COVID?
A: While more research is needed, maintaining a healthy lifestyle with a balanced diet, regular exercise, and limited antibiotic use can support a healthy microbiome.

Q: Are probiotics a guaranteed solution for Long COVID?
A: Not at this time. Probiotics may be helpful for some individuals, but more research is needed to determine the most effective strains and dosages.

Q: Is Long COVID always caused by a bacterial imbalance?
A: No. Long COVID is a complex condition with multiple potential causes, including persistent viral reservoirs, autoimmunity, and tissue damage.

Did you know? Long COVID affects an estimated 15 million Americans, according to recent data from the U.S. Department of Health and Human Services.

Explore further: Read more about the latest research on Long COVID and the microbiome here.

Have you experienced Long COVID? Share your story and insights in the comments below!

0 comments
0 FacebookTwitterPinterestEmail
Tech

DNA origami vaccine platform shows promise against multiple infectious viruses

by Chief Editor
written by Chief Editor

Beyond COVID-19: The Next Generation of mRNA and DNA Vaccine Technology

The rapid development and deployment of mRNA vaccines during the COVID-19 pandemic marked a turning point in global healthcare. These vaccines, initially administered in December 2020, are estimated to have prevented at least 14.4 million deaths in the first year alone. This success has spurred research into applying mRNA technology to a wider range of infectious diseases, including influenza, RSV, HIV, Zika, Epstein-Barr virus, and tuberculosis. However, recent research suggests that improvements to mRNA vaccine technology are needed, paving the way for innovative platforms like DoriVac.

Introducing DoriVac: A DNA Nanotechnology Approach

Developed by researchers at the Wyss Institute at Harvard University and Dana-Farber, DoriVac is a DNA nanotechnology-enabled vaccine platform designed for broad applicability. The platform offers unprecedented control over vaccine composition and the ability to program immune recognition in targeted immune cells. DoriVac vaccines consist of tiny, self-folding DNA nanostructures presenting adjuvant molecules and antigens with optimized spacing.

How DoriVac Works

DoriVac’s design presents immune-boosting adjuvant molecules with nanoscale precision to cells, eliciting highly beneficial immune responses. In tumor-bearing mice, DoriVac vaccines exceeded the performance of vaccines without the origami structure. The nanostructures present adjuvants on one face and antigens – derived from pathogens or tumors – on the opposite face.

Leveraging DoriVac Against Viral Threats

Researchers tested DoriVac’s potential in infectious disease settings by designing vaccines specific to SARS-CoV-2, HIV, and Ebola. These vaccines presented HR2 peptides, which are highly conserved antigens found in the spike proteins of these viruses. Studies in mice showed that DoriVac vaccines triggered significantly greater and broader activation of both humoral and cellular immunity compared to vaccines without the DNA origami structure.

Specifically, the research demonstrated increased numbers of antibody-producing B cells, activated antigen-presenting dendritic cells, and antigen-specific memory and cytotoxic T cells – all crucial for long-term protection. The SARS-CoV-2 HR2 vaccine showed particularly promising results.

Predicting Human Immune Responses with Human LN Chips

Recognizing that immune responses can differ between mice and humans, the team utilized a human lymph node-on-a-chip (human LN Chip) to assess DoriVac’s effects in a human-relevant system. This technology allows for rapid preclinical prediction of immune responses in humans. Results showed that the SARS-CoV-2-HR2 DoriVac vaccine activated human dendritic cells and increased the production of inflammatory cytokine molecules to a greater extent than vaccines lacking the origami structure.

The human LN Chip also revealed increased numbers of CD4+ and CD8+ T cells with protective functions, further validating DoriVac’s potential for human applications. Researchers believe the predictive capabilities of the human LN Chip significantly increase the likelihood of success for this novel class of vaccines.

The Future of Vaccine Development

The convergence of DNA nanotechnology, advanced immunology, and microfluidic human Organ Chip technology represents a significant leap forward in vaccine development. The DoriVac platform, and technologies like it, offer the potential to create more effective and targeted vaccines against a wide range of diseases. This approach could also accelerate the development of personalized vaccines tailored to individual immune profiles.

Pro Tip:

Nanotechnology in vaccines isn’t just about delivering antigens; it’s about controlling how the immune system sees them, leading to more precise and powerful responses.

FAQ

Q: What is DoriVac?
A: DoriVac is a DNA nanotechnology-enabled vaccine platform that offers precise control over vaccine composition and immune response.

Q: How does DoriVac differ from traditional mRNA vaccines?
A: DoriVac utilizes DNA origami to present antigens and adjuvants with nanoscale precision, potentially leading to stronger and more targeted immune responses.

Q: What is a human LN Chip?
A: A human lymph node-on-a-chip is a microfluidic device that mimics the human lymph node, allowing researchers to predict immune responses in a human-relevant system.

Q: What diseases is DoriVac being developed for?
A: Initial research focuses on SARS-CoV-2, HIV, and Ebola, but the platform is designed to be adaptable to a wide range of infectious diseases and potentially cancer.

Did you know? The DoriVac platform was initially developed for cancer applications before being adapted for infectious diseases during the COVID-19 pandemic.

Explore more about the Wyss Institute’s groundbreaking research here.

0 comments
0 FacebookTwitterPinterestEmail
Health

The winter dare that leaves kids’ tongues stuck to metal

by Chief Editor
written by Chief Editor

The Surprisingly Persistent Danger of “Tundra Tongue”: A Deep Dive into a Centuries-Old Phenomenon

For generations, the dare of touching your tongue to a frozen metal object has been a rite of passage for children in colder climates. But beneath the playful challenge lies a real, albeit often minor, risk. A recent scoping review of historical newspaper reports – spanning over 250 years – reveals a surprisingly consistent pattern of “tundra tongue” incidents, prompting renewed calls for preventative education and awareness.

A History Frozen in Time: Tracking Tundra Tongue Through the Ages

The term “tundra tongue” itself is relatively recent, coined by a researcher after experiencing the icy adhesion firsthand. However, reports of tongues freezing to metal date back to at least 1845, with the earliest documented case involving a French schoolboy and a metal bridge. The peak of reported incidents occurred in the 1950s, though the reasons for this spike remain unclear. Interestingly, a decline in reported cases doesn’t necessarily correlate with safety regulations, as most incidents don’t involve playground equipment.

Who’s Most at Risk? Demographics of a Cold-Weather Mishap

The data paints a clear picture: children, particularly boys, are most susceptible to tundra tongue. The review analyzed 856 reports detailing 113 cases, finding that 96% involved children with a median age of 5.25 years. Boys accounted for 63% of the incidents. This suggests a combination of factors, including curiosity, risk-taking behavior, and potentially, a higher likelihood of engaging in dares.

Where Does it Happen? Common Surfaces and Temperatures

Railings are the most common culprits, accounting for 40% of reported cases, followed by fences (13%). Lamp posts and other metal objects similarly pose a risk. The incidents aren’t limited to outdoor settings, with one case involving children suffering tongue lacerations after contact with dry ice used to store ice cream. The median ambient temperature during these incidents was -16.5 °C, and tundra tongue was rarely observed at temperatures above -8 °C.

Beyond the Initial Stick: Potential Injuries and Outcomes

While most cases result in discomfort and mild bleeding, more severe injuries can occur. These include direct tissue damage from freezing, injuries sustained during forceful detachment, and complications arising from prolonged immobility. Approximately 18% of cases involved medical attention, with some requiring hospital visits, stitches, or even partial tongue removal. In rare instances, systemic infections have developed.

What to Do (and Not Do) When a Tongue Gets Stuck

The key is to avoid panic and forceful removal. Pulling a tongue free quickly can cause significant tearing. The recommended approach involves warming the metal surface with warm water (not hot – above 0 °C but below 45–50 °C) or, if water isn’t available, breathing on the metal or cupping hands around it. Using harmful liquids or attempting to cut the tongue free with tools like penknives should be avoided.

The Role of Regulation and Public Awareness

In the 1990s, Norway implemented regulations requiring insulation on playground equipment, sparked by concerns over tundra tongue. While effective for playgrounds, this addresses only a fraction of the potential risk areas. Raising public awareness, particularly among parents and educators, remains crucial. Simple education about the dangers and safe removal techniques can significantly reduce the incidence of severe injuries.

Future Research: Filling the Gaps in Our Understanding

Despite the long history of reported cases, surprisingly little scientific research has been conducted on tundra tongue. Further investigation is needed to understand the physiological effects of extreme cold on tongue tissue, to develop evidence-based first-aid guidelines, and to identify effective preventative measures. The use of models, such as those employing pig tongues in laboratory settings, can provide valuable insights without risking human subjects.

FAQ: Your Questions About Tundra Tongue Answered

  • What is tundra tongue? It’s the common name for the phenomenon of a tongue adhering to a cold metal surface.
  • Is it dangerous? Most cases are not serious, but forceful removal can cause injury.
  • Who is most at risk? Children, especially boys around the age of five.
  • What should I do if my child’s tongue gets stuck? Warm the metal surface with warm water or breath, and avoid pulling the tongue free.
  • Are there any long-term effects? Severe cases can lead to scarring or infection, but most heal without lasting complications.

Pro Tip: If you suspect your child has suffered a tongue injury, even a minor one, consult a medical professional to rule out any complications.

Have you or someone you know experienced tundra tongue? Share your story in the comments below!

0 comments
0 FacebookTwitterPinterestEmail
Newer Posts
Older Posts